Drug Profile
D2A21
Alternative Names: D2A21 gel - Demegen; Demegel; Peptidyl MIM; ProvenaLatest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Demegen
- Developer Demegen; DFB Pharmaceuticals
- Class Antibacterials; Antineoplastics; Peptide antibiotics
- Mechanism of Action Apoptosis stimulants; Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Burn infections
- No development reported Bacterial infections
- Discontinued Cancer; Protozoan infections
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Topical, Gel)
- 13 Jul 2017 D2A21 is still in Preclinical trials for Bacterial infections in USA (Demegen pipeline, July 2017)
- 13 Jul 2017 Phase-III clinical trials in Burn infections in USA (Topical) before July 2017 (Demegen pipeline, July 2017)